Johnson & Johnson Is Refocusing Its Business Strategy
Johnson & Johnson (JNJ) has shifted its self-identification from being broadly labeled as 'a health care company' to positioning itself as an innovation powerhouse in medicine. This change reflects a strategic narrowing of focus, particularly on the pharmaceutical side of the business, which accounts for about two-thirds of revenue and is growing faster than the medical device segment. The orthopedics division—part of MedTech—is being separated from JNJ with plans to complete by mid-2027. While this unit has shown recent growth, it remains slower compared to Innovative Medicine. Management aims to become number one in oncology by 2030 and is raising full-year sales guidance despite challenges within the cardiovascular segment. The company's performance continues strong with a stock up nearly 60% year-to-date versus about 20% for the S&P 500, but investors should be aware that post-2027 JNJ will likely represent a more concentrated and potentially riskier portfolio.
Tickers: $JNJ
Topics: Johnson & Johnson MedTech separation revenue breakdown strategic focus shift